US FDA seeks more information on Telix Pharma’s diagnostic drug for kidney cancer (Reuters) -The U.S. Food and Drug Administration has requested additional data from Telix Pharmaceuticals on its application for a diagnostic drug to detect a form of kidney cancer, the Australian cancer diagnostics firm said on Thursday. The U.S. drug regulator cited deficiencies relating to its manufacturing and supply chain processes, and requested additional data to prove that the scaled-up commercial manufacturing process is comparable to the one used in clinical trials. Shares of the Sydney-listed diagnostics firm plunged as much as 24% in early trade on Thursday, marking their worst intra-day decline on record. They were last trading 14% lower at A$15.80, and were the worst performers in the ASX 200 benchmark index. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. ProPicks AI analyzes thousands of stocks using 100+ institutional-grade financial metrics to identify the strongest opportunities. With 80+ strategies across global markets, you might be surprised where TLX appears. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Each strategy refreshes monthly with 10-20 high-conviction picks. Even if TLX isn't currently featured, you'll discover similar opportunities in the same industry or theme—stocks the AI identifies before they breakout. Now up to 50% off while our Summer Sale lasts.

Click Subscribe #FDA #TelixPharma #KidneyCancer #CancerResearch #Pharmaceuticals

Telix Pharma slides 10% on SEC probe into cancer treatment Investing.com-- Australian shares of Telix Pharmaceuticals Ltd (ASX:TLX) fell sharply on Wednesday after the company said it was hit with a U.S. Securities and Exchange Commission probe over its prostate cancer treatment. Telix’s shares slid 10.3% to A$22.530, lagging a 0.7% rise in the ASX 200 index. Telix said on Tuesday that the SEC had issued it with a subpoena regarding the company’s disclosures of its prostate cancer therapies, stating that it was a “fact-finding request.” More information on the probe was not disclosed, and the company said it was cooperating with the agency. “We cannot predict when this matter will be resolved or what (if any) action the SEC may take following the conclusion of this investigation,” Telix said in a statement, adding that the company will continue with the clinical development of its prostate cancer treatments. The company said that the probe does not extend to its commercial and late-stage treatments. News of the probe largely offset strong second-quarter earnings from the pharma firm, which clocked a 63% jump in revenue. The company also reaffirmed its 2025 revenue guidance of $770 million to $800 million. Telix’s American Depository Receipts (NASDAQ:TLX) fell 1.3% on Tuesday. Before you buy stock in TLX, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is TLX one of them?

Click Subscribe #TelixPharma #CancerTreatment #SECProbe #Pharmaceuticals #StockMarket